# OnCo record linvoseltamab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/linvoseltamab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "linvoseltamab" ;
  schema:name "Linvoseltamab"@en ;
  schema:description "Linvoseltamab is Regeneron's BCMA bispecific, approved in July 2025 with the highest complete-response rate of the class in its pivotal study."@en ;
  schema:url <https://onco.cc/drugs/linvoseltamab/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Linvoseltamab> ;
  onco:status "approved" ;
  onco:modality "Bispecific T-cell engager (BCMA×CD3)" ;
  schema:alternateName "Lynozyfic" ;
  onco:approval "US 2025: Relapsed/refractory myeloma after ≥4 lines (accelerated)", "EU 2025: R/R myeloma ≥3 lines; 23 Apr 2025 (conditional)" ;
  onco:acceleratedApproval "US 2025-07-02: Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody." ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/myeloma-relapsed-refractory/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/> ;
  onco:targets <https://onco.cc/targets/bcma/>, <https://onco.cc/targets/cd3/> ;
  onco:companies <https://onco.cc/companies/regeneron/> ;
  onco:terms <https://onco.cc/terms/pivotal-trial/> ;
  onco:trials <https://onco.cc/trials/linker-mm1/>, <https://onco.cc/trials/nct05730036/>, <https://onco.cc/trials/nct07393282/>, <https://onco.cc/trials/nct06140524/>, <https://onco.cc/trials/nct05955508/>, <https://onco.cc/trials/nct06669247/>, <https://onco.cc/trials/nct05828511/>, <https://onco.cc/trials/nct07455851/> .